Annual ROE
-61.02%
-18.54%-43.64%
December 31, 2022
Summary
- As of February 10, 2025, NLTX annual return on equity is -61.02%, with the most recent change of -18.54% (-43.64%) on December 31, 2022.
- During the last 3 years, NLTX annual ROE has fallen by -12.01% (-24.51%).
Performance
NLTX ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly ROE
-41.46%
+5.98%+12.61%
September 30, 2023
Summary
- As of February 10, 2025, NLTX quarterly return on equity is -41.46%, with the most recent change of +5.98% (+12.61%) on September 30, 2023.
- Over the past year, NLTX quarterly ROE has increased by +6.41% (+13.39%).
Performance
NLTX Quarterly ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
ROE Formula
ROE = Net Income
Shareholders Equity ✕ 100%
Shareholders Equity ✕ 100%
NLTX ROE Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -43.6% | +13.4% |
| 3 y3 years | -24.5% | -119.3% |
| 5 y5 years | -20.2% | +15.1% |
NLTX ROE Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | +43.6% | at low | +9.9% | +36.7% |
| 5 y | 5-year | +250.7% | at low | +119.2% | +90.1% |
| alltime | all time | -356.9% | +8.0% | -113.4% | +256.9% |
Neoleukin Therapeutics ROE History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2023 | - | -41.46%(-12.6%) |
| Jun 2023 | - | -47.44%(-16.3%) |
| Mar 2023 | - | -56.69%(+10.0%) |
| Dec 2022 | -61.02%(+43.6%) | -51.53%(+7.6%) |
| Sep 2022 | - | -47.87%(+5.7%) |
| Jun 2022 | - | -45.29%(+10.2%) |
| Mar 2022 | - | -41.08%(+8.9%) |
| Dec 2021 | -42.48%(+144.1%) | -37.71%(+12.2%) |
| Sep 2021 | - | -33.62%(+37.8%) |
| Jun 2021 | - | -24.39%(+7.7%) |
| Mar 2021 | - | -22.65%(+11.9%) |
| Dec 2020 | -17.40%(-64.5%) | -20.25%(+7.1%) |
| Sep 2020 | - | -18.91%(-73.8%) |
| Jun 2020 | - | -72.20%(-0.6%) |
| Mar 2020 | - | -72.61%(-7.9%) |
| Dec 2019 | -49.01%(+33.1%) | -78.81%(-15.7%) |
| Sep 2019 | - | -93.47%(+210.2%) |
| Jun 2019 | - | -30.13%(+22.4%) |
| Mar 2019 | - | -24.61%(-36.5%) |
| Dec 2018 | -36.82% | -38.77%(-20.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2018 | - | -48.81%(+19.4%) |
| Jun 2018 | - | -40.88%(-23.4%) |
| Mar 2018 | - | -53.37%(+26.2%) |
| Dec 2017 | -50.75%(+98.4%) | -42.30%(+21.8%) |
| Sep 2017 | - | -34.72%(+17.5%) |
| Jun 2017 | - | -29.54%(+1.2%) |
| Mar 2017 | - | -29.19%(-2.5%) |
| Dec 2016 | -25.58%(+26.9%) | -29.93%(+9.1%) |
| Sep 2016 | - | -27.43%(+1.0%) |
| Jun 2016 | - | -27.16%(+7.4%) |
| Mar 2016 | - | -25.28%(-19.5%) |
| Dec 2015 | -20.16%(-69.4%) | -31.42%(-33.3%) |
| Sep 2015 | - | -47.14%(-37.2%) |
| Jun 2015 | - | -75.10%(+14.8%) |
| Mar 2015 | - | -65.43%(+27.2%) |
| Dec 2014 | -65.90%(-389.8%) | -51.43%(-49.0%) |
| Sep 2014 | - | -100.76%(-31.9%) |
| Jun 2014 | - | -147.96%(-147.8%) |
| Mar 2014 | - | 309.62%(+1261.6%) |
| Dec 2013 | 22.74%(-4.3%) | 22.74% |
| Dec 2012 | 23.75% | - |
FAQ
- What is Neoleukin Therapeutics annual return on equity?
- What is the all time high annual ROE for Neoleukin Therapeutics?
- What is Neoleukin Therapeutics annual ROE year-on-year change?
- What is Neoleukin Therapeutics quarterly return on equity?
- What is the all time high quarterly ROE for Neoleukin Therapeutics?
- What is Neoleukin Therapeutics quarterly ROE year-on-year change?
What is Neoleukin Therapeutics annual return on equity?
The current annual ROE of NLTX is -61.02%
What is the all time high annual ROE for Neoleukin Therapeutics?
Neoleukin Therapeutics all-time high annual return on equity is 23.75%
What is Neoleukin Therapeutics annual ROE year-on-year change?
Over the past year, NLTX annual return on equity has changed by -18.54% (-43.64%)
What is Neoleukin Therapeutics quarterly return on equity?
The current quarterly ROE of NLTX is -41.46%
What is the all time high quarterly ROE for Neoleukin Therapeutics?
Neoleukin Therapeutics all-time high quarterly return on equity is 309.62%
What is Neoleukin Therapeutics quarterly ROE year-on-year change?
Over the past year, NLTX quarterly return on equity has changed by +6.41% (+13.39%)